FDA inspection
Onyx Pharmaceuticals, Inc., a Subsidiary of Amgen, Inc.: FDA inspection ending Oct 22, 2002
FDA inspection 244719 · Voluntary Action Indicated (VAI) · South San Francisco, CA
Key facts
| Inspection ID | 244719 |
|---|---|
| Firm | Onyx Pharmaceuticals, Inc., a Subsidiary of Amgen, Inc. |
| FEI number | 3009255166 |
| Address | Onyx Pharmaceuticals, Inc., 249 E Grand Ave |
| City | South San Francisco |
| State | CA |
| ZIP | 94080-4804 |
| Fiscal year | 2003 |
| Inspection end date | Oct 22, 2002 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Human Cellular, Tissue and Gene Therapies |
| Product type | Biologics, Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data